entertainment -WSS

entertainment

author：entertainment 2025-10-02 17:27:22 - browse：7491

LONDON — AstraZeneca said on Monday that a new lung cancer treatment outperformed standard-of-care chemotherapy in a trial, but investors found the results less impressive than anticipated, sending company shares down in early trading.

Based on an interim analysis of a Phase 3 trial, the company said that the drug, datopotamab deruxtecan, led to improvement in progression-free survival in patients non-small cell lung cancer, a primary endpoint of the study. There was also a positive early trend on overall survival, with Susan Galbraith, AstraZeneca’s oncology leader, describing the results as “compelling evidence for the potential role” that the drug could play for patients.

But investors had been hoping for a clearer signal of benefit. Analysts noted that despite the success in progression-free survival, it was not described as a “clinically meaningful” improvement, which, as J.P. Morgan analysts wrote, “we believe the market would have liked to have seen.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Cord blood banking comes at a high cost to babies

hotspot

WSS

How to increase colonoscopy rates? Looks like an AI can help

Ionis drug prevents swelling attacks due to hereditary angioedema

Change Healthcare can notify patients about the breach, HHS says

Change Healthcare can notify patients about the breach, HHS says

Dems pitch expanding Medicare power to negotiate drug prices

Ultragenyx gene therapy for rare liver ailment succeeds in late

focus

entertainment

explore

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

ASCO: AstraZeneca says CAR

ChatGPT in medicine: STAT answers readers' burning questions

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

Activists slam private health insurers over coverage restrictions

NIH documents show early flaws of $1.6 billion long Covid program

Supreme Court strikes down use of affirmative action

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

hotspot

Shifting the focus from loneliness to social health

Innovation in antibiotics is ailing. 'Brain drain' may kill it

'Investigate these claims': UFO transparency at center of House hearing

BMI, flaws aside, is found to be useful estimate of body fat in youth

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

leisure time

hotspot

leisure time

hotspot